ZA200907743B - Formulation of sugar solutions for continuous ultracentrifugation for virus purification - Google Patents

Formulation of sugar solutions for continuous ultracentrifugation for virus purification

Info

Publication number
ZA200907743B
ZA200907743B ZA200907743A ZA200907743A ZA200907743B ZA 200907743 B ZA200907743 B ZA 200907743B ZA 200907743 A ZA200907743 A ZA 200907743A ZA 200907743 A ZA200907743 A ZA 200907743A ZA 200907743 B ZA200907743 B ZA 200907743B
Authority
ZA
South Africa
Prior art keywords
formulation
sugar solutions
virus purification
continuous ultracentrifugation
ultracentrifugation
Prior art date
Application number
ZA200907743A
Other languages
English (en)
Inventor
Manfred Reiter
Leopold Grillberger
Wolfgang Mundt
Artur Mitterer
Horst Schafhauser
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596388&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200907743(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of ZA200907743B publication Critical patent/ZA200907743B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14311—Parvovirus, e.g. minute virus of mice
    • C12N2750/14351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16251—Methods of production or purification of viral material
    • C12N2760/16252—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
ZA200907743A 2007-05-04 2009-11-04 Formulation of sugar solutions for continuous ultracentrifugation for virus purification ZA200907743B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92769207P 2007-05-04 2007-05-04

Publications (1)

Publication Number Publication Date
ZA200907743B true ZA200907743B (en) 2010-09-29

Family

ID=39596388

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200907743A ZA200907743B (en) 2007-05-04 2009-11-04 Formulation of sugar solutions for continuous ultracentrifugation for virus purification

Country Status (18)

Country Link
US (4) US20100239609A1 (ko)
EP (1) EP2155864B1 (ko)
JP (2) JP5745717B2 (ko)
KR (4) KR101998537B1 (ko)
CN (2) CN101688187A (ko)
AR (1) AR066449A1 (ko)
AU (1) AU2008248904B2 (ko)
BR (1) BRPI0811499B8 (ko)
CA (1) CA2687119C (ko)
CL (1) CL2008001294A1 (ko)
HK (2) HK1138318A1 (ko)
IL (1) IL201898A (ko)
MX (1) MX2009011897A (ko)
PE (1) PE20090284A1 (ko)
RU (1) RU2503719C2 (ko)
TW (1) TWI472620B (ko)
WO (1) WO2008135229A2 (ko)
ZA (1) ZA200907743B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100239609A1 (en) * 2007-05-04 2010-09-23 Baxter International Inc. Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification
US20110293660A1 (en) * 2009-02-06 2011-12-01 Bruno Rene Andre Novel method
US9644187B2 (en) 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
CN101948813B (zh) * 2010-09-04 2012-07-25 国家海洋局第一海洋研究所 一种刺参球形病毒的分离方法
WO2016096688A1 (en) 2014-12-16 2016-06-23 Glaxosmithkline Biologicals S.A. A method for a large scale virus purification
EP3255054A1 (en) * 2016-06-06 2017-12-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the purification of biological macromolecular complexes
SG11201903890QA (en) * 2016-11-04 2019-05-30 Baxalta Inc Adeno-associated virus purification methods
KR102590519B1 (ko) 2017-03-03 2023-10-17 다케다 야쿠힌 고교 가부시키가이샤 아데노-연관 바이러스 제제의 효력을 결정하는 방법
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法
WO2022229703A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. New aav8 based immune escaping variants
WO2022229702A2 (en) 2021-04-30 2022-11-03 Takeda Pharmaceutical Company, Ltd. Aav8 capsid variants with enhanced liver targeting
AU2022364731A1 (en) * 2021-10-12 2024-05-02 Cytonus Therapeutics, Inc. Systems and methods for manufacturing of therapeutic cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
ATE1882T1 (de) * 1978-05-08 1982-12-15 Merck & Co. Inc. Ein verfahren zur direkten extraktion von kleinen teilchen bis 50 nm aus einer proteinhaltigen fluessigkeit.
US4217418A (en) * 1978-05-08 1980-08-12 Merck & Co., Inc. Recovery of small particles by flow centrifugation
JPH06247995A (ja) * 1991-06-24 1994-09-06 Asahi Chem Ind Co Ltd 新規なシアリル（α２−６）ラクトテトラオシルセラミド
RU2080124C1 (ru) * 1995-10-19 1997-05-27 Санкт-Петербургский научно-исследовательский институт вакцин и сывороток Способ получения живой гриппозной вакцины
ES2377968T3 (es) * 2003-04-01 2012-04-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Anticuerpos dirigidos contra el complejo E1E2 del virus de la hepatitis C y composiciones farmacéuticas
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
CN1739801A (zh) * 2004-08-27 2006-03-01 上海生物制品研究所 一种流行性感冒病毒裂解疫苗及其制备方法
US20100239609A1 (en) * 2007-05-04 2010-09-23 Baxter International Inc. Formulation of Sugar Solutions for Continuous Ultracentrifugation for Virus Purification

Also Published As

Publication number Publication date
BRPI0811499A2 (pt) 2014-10-14
KR101998537B1 (ko) 2019-07-09
US20100239609A1 (en) 2010-09-23
CA2687119C (en) 2021-06-08
US20160060603A1 (en) 2016-03-03
KR101744430B1 (ko) 2017-06-20
KR20170065671A (ko) 2017-06-13
US8969533B2 (en) 2015-03-03
TWI472620B (zh) 2015-02-11
PE20090284A1 (es) 2009-03-17
HK1211320A1 (en) 2016-05-20
TW200914615A (en) 2009-04-01
HK1138318A1 (en) 2010-08-20
WO2008135229A3 (en) 2008-12-31
JP2010525798A (ja) 2010-07-29
AU2008248904A1 (en) 2008-11-13
BRPI0811499B1 (pt) 2019-06-04
CL2008001294A1 (es) 2009-03-06
CN101688187A (zh) 2010-03-31
US20080274138A1 (en) 2008-11-06
AU2008248904B2 (en) 2014-10-09
KR20180077305A (ko) 2018-07-06
IL201898A (en) 2013-11-28
CN104694489A (zh) 2015-06-10
RU2009144980A (ru) 2011-06-10
WO2008135229A2 (en) 2008-11-13
RU2503719C2 (ru) 2014-01-10
JP2015061538A (ja) 2015-04-02
JP5745717B2 (ja) 2015-07-08
JP6031082B2 (ja) 2016-11-24
IL201898A0 (en) 2011-08-01
KR20150082676A (ko) 2015-07-15
US9732327B2 (en) 2017-08-15
BRPI0811499B8 (pt) 2021-05-25
EP2155864B1 (en) 2013-07-17
MX2009011897A (es) 2010-02-04
KR20100017594A (ko) 2010-02-16
CA2687119A1 (en) 2008-11-13
KR101873891B1 (ko) 2018-07-04
EP2155864A2 (en) 2010-02-24
AR066449A1 (es) 2009-08-19
US20170369853A1 (en) 2017-12-28

Similar Documents

Publication Publication Date Title
HK1211320A1 (en) Formulation of sugar solutions for continuous ultracentrifugation for virus purification
HK1156038A1 (en) Compounds and pharmaceutical compositions for the treatment of viral infections
EP2334328A4 (en) METHOD FOR CLEANING VIRUSES
PL3192874T3 (pl) Oczyszczanie wirusa
HK1142001A1 (en) Preparation for transnasal application
IL206478A0 (en) Processes for the preparation and purification of paliperidone palmitate
HK1144794A1 (en) Devices for treatment of viral infections
ZA201104348B (en) Pharmaceutical preparation
EP2197283A4 (en) FORMULATIONS FOR THE PRESERVATION OF ROTAVIRES
ZA201006827B (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
ZA201007610B (en) Processes for the preparation of benzo-fused dioxin derivatives
GB0815972D0 (en) Pharmaceutical preparation
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
IL205082A0 (en) Process for the preparation of tetranorlabdane derivatives
GB0900503D0 (en) Thermal treatment of integral rotors
HUP0700756A2 (en) Process for the preparation of pharmaceutical intermediers
IL213128A0 (en) Processes for the preparation and purification of gabapentin enacarbil
HK1156250A1 (en) Unit dosage of apadenoson
HK1131039A1 (en) Pharmaceutical use of sophoricoside
PL2896614T3 (pl) Sposoby i związki do wytwarzania normorfinanów
HK1139050A1 (en) Medicament for the treatment of pneumonia
EP2331490A4 (en) PREPARATION OF DIBUTOXYMETHANE
AU2013257527A1 (en) Unit dosage of apadenoson
GB0717955D0 (en) Preparation of modified nucleosides
TH111563B (th) กรรมวิธีสำหรับการเตรียมไตรออกเซนก่อนการทำให้บริสุทธิ์